Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas

Inclusion Criteria: * Age ≥18 and ≤65 years * Clinical diagnosis of Type 1 Diabetes for at least one year * Currently using an insulin pump for at least 6 months * Uses insulin parameters such as carbohydrate ratio and correction factors consistently on their insulin pump in order to dose insulin for meals or corrections * Access to internet and willingness to upload data during the study * Willingness to be physically active for at least 30 minutes per day at least 4 times per week * Willingness to perform the required exercise regimen during Data Collection Period * Willingness to not perform regular exercise outside of the study-regimented exercise window * For females, not currently pregnant or breastfeeding. If a female is of child-bearing potential and sexually active, she must agree to use a form of contraception to prevent pregnancy while participating in the study. * An understanding and willingness to follow the protocol and sign informed consent. Exclusion Criteria: * History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment. * Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment. * Pregnancy or intent to become pregnant during the trial. * Currently being treated for a seizure disorder * Coronary artery disease or heart failure, unless written clearance is received from a cardiologist or primary care provider and documentation of a negative stress test within the year * History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted) * Clinically significant electrocardiogram (ECG) at time of Screening, as interpreted by the study medical physician. * Use of non-insulin glucose-lowering agent (including GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals) with the exception of participants who have been on a stable dose of Metformin for at least 3 months. * A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: * Inpatient psychiatric treatment in the past 6 months * Presence of a known adrenal disorder * Abnormal liver function test results (Transaminase \>2 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function * Uncontrolled thyroid disease * Use of an automated insulin delivery mechanism that is not FDA approved during the data collection phase * Use of an automated insulin delivery mechanism that is not downloadable by the subject or study team * Inability to be physically active for at least 30 minutes per day for at least 4 times per week * Current enrollment in another clinical trial, unless approved by the investigators of both studies or if clinical trial is a non-interventional registry trial.